These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 36152419)
1. Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS). Jones A; Peers K; Wierzbicki AS; Ramachandran R; Mansfield M; Dawson C; Ochoa-Ferraro A; Soran H; Jenkinson F; McDowell I; Downie P; Hamilton P; Jones RD Atherosclerosis; 2023 Jun; 375():67-74. PubMed ID: 37253281 [TBL] [Abstract][Full Text] [Related]
2. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial. Witztum JL; Gaudet D; Arca M; Jones A; Soran H; Gouni-Berthold I; Stroes ESG; Alexander VJ; Jones R; Watts L; Xia S; Tsimikas S J Clin Lipidol; 2023; 17(3):342-355. PubMed ID: 37100699 [TBL] [Abstract][Full Text] [Related]
3. Real-world safety and efficacy of lomitapide in homozygous familial hypercholesterolemia: interim report of special-use survey in Japan. Harada-Shiba M; Haruna S; Kogawa N Future Cardiol; 2024 Feb; 20(2):67-80. PubMed ID: 38420884 [TBL] [Abstract][Full Text] [Related]
4. Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia. Kameyama N; Maruyama C; Kitagawa F; Nishii K; Uenomachi K; Katayama Y; Koga H; Chikamoto N; Kuwata Y; Torigoe J; Arimoto M; Tokumaru T; Ikewaki K; Nohara A; Otsubo Y; Yanagi K; Yoshida M; Harada-Shiba M J Atheroscler Thromb; 2019 Jan; 26(1):72-83. PubMed ID: 29899183 [TBL] [Abstract][Full Text] [Related]
5. Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS). Bashir B; Kwok S; Wierzbicki AS; Jones A; Dawson C; Downie P; Jenkinson F; Delaney H; Mansfield M; Datta D; Teoh Y; Hamilton P; Forrester N; O'Sullivan D; Ferdousi M; Durrington PN; AbdelRazik A; Gallo A; Moulin P; Soran H Atherosclerosis; 2024 Apr; 391():117476. PubMed ID: 38447437 [TBL] [Abstract][Full Text] [Related]
6. Symptoms and impacts of familial chylomicronemia syndrome: a qualitative study of the patient experience. Williams K; Tickler G; Valdivielso P; Alonso J; Vera-Llonch M; Cubells L; Acaster S Orphanet J Rare Dis; 2023 Oct; 18(1):316. PubMed ID: 37817256 [TBL] [Abstract][Full Text] [Related]
7. Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28. Kaiser K; Fox RS; Perschon C; Vera-Llonch M; Alonso J; Cubells L; Cella D Qual Life Res; 2023 Feb; 32(2):605-614. PubMed ID: 36310187 [TBL] [Abstract][Full Text] [Related]
8. The Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr Munkhsaikhan U; Kwon YI; Sahyoun AM; Galán M; Gonzalez AA; Ait-Aissa K; Abidi AH; Kassan A; Kassan M Antioxidants (Basel); 2023 Jun; 12(6):. PubMed ID: 37372017 [TBL] [Abstract][Full Text] [Related]
9. Lomitapide: A Medication Use Evaluation and a Formulary Perspective. Esba LCA; Alharbi H Glob J Qual Saf Healthc; 2024 May; 7(2):59-62. PubMed ID: 38725887 [TBL] [Abstract][Full Text] [Related]